The world of cell therapy has been eclipsed by the early success of oncology companies specializing in adoptive T-cell therapy or ACT. Other companies focusing on various types of multipotent stem cells have been working in the shadows, with little support from the press or the investment community.
But that might be about to change. Mesoblast Ltd.recently posted positive results in a Phase III trial of MSC-100-IV,...